ERBB2 and breast cancer: Currently, in the advanced setting, innovative treatments are now available for the different subtypes of BC, including (but not limited to) ET combined with cyclin-dependent kinases 4/6 inhibitors in luminal tumors [16], new anti-HER2 drugs for HER2+ tumors, and immune checkpoint inhibitors combined with CT.